<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397279</url>
  </required_header>
  <id_info>
    <org_study_id>CLAVA</org_study_id>
    <nct_id>NCT01397279</nct_id>
  </id_info>
  <brief_title>Assessment of Liver Glucose Metabolism in Diabetic Subjects</brief_title>
  <acronym>CLAVA</acronym>
  <official_title>Assessment of Liver Glucose Metabolism in Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is associated with hepatic insulin resistance. One consequence of insulin
      resistance of the liver is an altered hepatic glucose metabolism. This study investigates
      whether the whole body (M-value) and hepatic insulin sensitivity obtained by hyperinsulinemic
      euglycemic clamp is influenced by a preceding intravenous glucose tolerance test (Botnia
      Clamp) in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hyperinsulinemic euglycemic clamp represents the gold standard for measuring peripheral
      insulin sensitivity. The insulin sensitivity is described by the M-value,which is calculated
      from glucose infusion rates during the last 30min of the clamp.

      Glucose is metabolised in the periphery: 50% by neural tissues, 20% by splanchnic bed and
      liver, 15% by skeletal muscle, 5% by adipose tissue and 10% by blood cells and other tissues.
      Under hyperinsulinemic conditions there is a strong shift in glucose utilization: 85%
      skeletal muscle and 15% by neural tissues, splanchnic bed and liver, adipose tissue, blood
      cells and other tissues. The contribution of skeletal muscle varies with different insulin
      sensitivity.

      We now want to investigate whether there is a difference in tissue-specific insulin
      sensitivity measured from a Botnia clamp (intravenous glucose tolerance test (ivGTT) and
      following clamp) and a single hyperinsulinemic euglycemic clamp? After a 60min ivGTT blood
      glucose levels in type 2 diabetic subjects are still elevated compared to baseline. High
      blood glucose levels can influence several parameters and may also affect insulin
      sensitivity. Until now, it is not proven, that the clamp preceding ivGTT does not have a
      significant influence on the M-value.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>M Value in hyperinsulinemic euglycemic clamp</measure>
    <time_frame>3h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin-suppressed endogenous glucose production (liver insulin sensitivity)</measure>
    <time_frame>3h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Newly Diagnosed Type 2 Diabetes (During the Last 12 Months)</condition>
  <arm_group>
    <arm_group_label>Botnia clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperinsulinemic euglycemic clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intravenous glucose tolerance test</intervention_name>
    <description>Administration of a 30% weight-adapted glucose bolus intravenously.</description>
    <arm_group_label>Botnia clamp</arm_group_label>
    <other_name>ivGTT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hyperinsulinemic euglycemic clamp</intervention_name>
    <description>Intravenous administration of 20% glucose and insulin over 3 hours</description>
    <arm_group_label>Botnia clamp</arm_group_label>
    <arm_group_label>hyperinsulinemic euglycemic clamp</arm_group_label>
    <other_name>HEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed type 2 diabetes (during the last 12 months)or non-diabetic subjects

        Exclusion Criteria:

          -  severe chronic diseases

          -  hepatitis B, C oder HIV infection

          -  malignancies

          -  immune suppressive therapy

          -  psychiatric illnesses

          -  drug or alcohol abuse

          -  anemia

          -  renal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Director German Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Roden, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director German Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>hyperinsulinemic euglycemic clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

